score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61L	0.3958	331.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0.0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0	0.0	0.0	0.0	NRAS p.Q61L (Missense)	1.0	MEL-IPI_Pat44	MEL-IPI_Pat44-Tumor-SM-4DK25	MEL-IPI_Pat44-Normal-SM-4NFVB
Putatively Actionable	Preclinical			Copy Number	CDKN2A	Deletion				0.0	0.0		Putatively Actionable	EPZ015666	PRMT5 inhibition	Targeted therapy	These deletions are typically codeleted with MTAP, which has enhanced dependency on PRMT5 for which there is an inhibitor in clincial development	Kryukov GV, Wilson FH, Ruth JR, et al. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science. 2016;351(6278):1214-8.	https://doi.org/10.1126/science.aad5214													0				CDKN2A Deletion		MEL-IPI_Pat44	MEL-IPI_Pat44-Tumor-SM-4DK25	
Putatively Actionable			Clinical evidence	Copy Number	MYC	Amplification				0.0	0.0																Putatively Actionable	0.0	Poor prognosis (< 15%) was observed for patients with amplified MYC with Medulloblastoma.	Ryan SL, Schwalbe EC, Cole M, et al. MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastoma. Acta Neuropathol. 2012;123(4):501-13.	https://doi.org/10.1007/s00401-011-0923-y	0				MYC Amplification		MEL-IPI_Pat44	MEL-IPI_Pat44-Tumor-SM-4DK25	
Investigate Actionability	Preclinical			Somatic Variant	AKT1	Missense	p.Y112H	0.4796	269.0	0.0	0.0		Investigate Actionability	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230													0	0.0	0.0	0.0	AKT1 p.Y112H (Missense)	0.0	MEL-IPI_Pat44	MEL-IPI_Pat44-Tumor-SM-4DK25	MEL-IPI_Pat44-Normal-SM-4NFVB
Biologically Relevant				Somatic Variant	ROS1	Missense	p.D1538N	0.8571	49.0	0.0	0.0																					0	0.0	0.0	0.0	ROS1 p.D1538N (Missense)		MEL-IPI_Pat44	MEL-IPI_Pat44-Tumor-SM-4DK25	MEL-IPI_Pat44-Normal-SM-4NFVB
Biologically Relevant				Copy Number	ROS1	Deletion				0.0	0.0																					0				ROS1 Deletion		MEL-IPI_Pat44	MEL-IPI_Pat44-Tumor-SM-4DK25	
Biologically Relevant				Microsatellite Stability	Supporting variants		PRDM2 p.703_704insP (Insertion)																									0				Supporting variants: PRDM2 p.703_704insP (Insertion)		MEL-IPI_Pat44		
Biologically Relevant				Mutational Signature	COSMIC Signature 1	version 2	0.28																									0				COSMIC Signature (version 2) 1 (28%)		MEL-IPI_Pat44		
Biologically Relevant				Mutational Signature	COSMIC Signature 7	version 2	0.72																									0				COSMIC Signature (version 2) 7 (72%)		MEL-IPI_Pat44		
